Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in COPD patients with prior exacerbations
2015-001122-42Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Lebrikizumab with Placebo (2 arms). Primary endpoint: Absolute change in pre-bronchodilator FEV1 from baseline to Week 12. Started Aug 2015; status: completed.
02
Drugs
lebrikizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2015-001122-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001122-42.